A phase 1 dose-expansion trial evaluated intratumoral NBTXR3 followed by definitive radiation therapy in 56 patients with locally-advanced mucosal squamous cell carcinoma of head and neck ineligible for cisplatin and cetuximab reporting a 64% complete response and median progression-free survival surpassing 11 months, supporting ongoing phase 3 evaluation. | Christophe Le Tourneau, JAMA Otolaryngol Head Neck Surg
